CBR3
CBR3 (carbonyl reductase 3, also known as SDR21C2) is a cytoplasmic, NADPH-dependent oxidoreductase of the short-chain dehydrogenase/reductase family. It reduces carbonyl compounds, including quinones and some drugs, to their corresponding alcohols. Browse Assay Genie's current range of CBR3 research reagents below, or read on for the biology behind the target.
CBR3 catalyses the NADPH-dependent reduction of carbonyl compounds to their corresponding alcohols. NCBI describes it as acting on a large number of biologically and pharmacologically active carbonyl compounds, and classifies it as a monomeric NADPH-dependent oxidoreductase. UniProt also notes low NADPH-dependent oxidoreductase activity.
The enzyme acts on several ortho-quinones and on non-quinone compounds such as isatin and the anticancer drug oracin. Its best substrate is 1,2-naphthoquinone. It is active toward ortho-quinones but not para-quinones. This substrate profile suggests a role in protection against the cytotoxicity of exogenous quinones. Isatin is the only endogenous substrate identified so far, so the physiological role of CBR3 remains open. This is a useful point when you design experiments around the CBR3 protein.
CBR3 belongs to the short-chain dehydrogenase/reductase (SDR) superfamily and is localised to the cytoplasm. The CBR3 gene has three exons and lies close to another carbonyl reductase gene, CBR1. Orthologous Cbr3 genes are found in mouse and rat, which allows comparative work in rodent models. The symbol SDR21C2 is an alias that reflects its place in the SDR nomenclature.
Researchers studying quinone metabolism, drug reduction or carbonyl reductase biology often look at CBR3 alongside CBR1, since the two genes are closely linked.
CBR3 reduces ortho-quinones such as 1,2-naphthoquinone, so it is studied for a possible role in protection against exogenous quinone cytotoxicity.
The enzyme acts on pharmacologically active carbonyl compounds, including the anticancer drug oracin, making it relevant to studies of drug reduction.
As a monomeric NADPH-dependent member of the short-chain dehydrogenase/reductase family, CBR3 is used to examine substrate specificity among carbonyl reductases.
Isatin is the only endogenous CBR3 substrate identified so far, which leaves its physiological function an open research question.
CBR3 catalyses the NADPH-dependent reduction of carbonyl compounds to their corresponding alcohols. It acts on ortho-quinones, isatin and the drug oracin, and is best with 1,2-naphthoquinone. It may help protect against exogenous quinone cytotoxicity, but only isatin has been identified as an endogenous substrate.
CBR3 is the HGNC symbol for carbonyl reductase 3, and SDR21C2 is a listed alias. UniProt names the protein carbonyl reductase [NADPH] 3, and the enzyme carries the EC number 1.1.1.184. It belongs to the short-chain dehydrogenase/reductase superfamily.
Mouse and rat both have a Cbr3 ortholog. In humans, the CBR3 gene is closely linked to another carbonyl reductase gene, CBR1. Check the datasheet of any product for its validated reactivity.
CBR1, the closely linked carbonyl reductase gene, and other targets in related pathways with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O75828; product specifications from Assay Genie datasheets.